东曜药业-B(01875)与药明合联(02268)订立工艺开发及制造服务协议

智通财经

Jun 17

智通财经APP讯，东曜药业-B(01875)及药明合联(02268)联合公布，2026年6月16日，东曜药业与药明生物订立工艺开发及制造服务协议，据此，东曜药业将向药明生物提供工艺开发及制造服务。

根据工艺开发及制造服务协议，东曜药业同意向药明生物提供有关单克隆抗体中间体生产的工艺开发及制造服务。该等服务涵盖细胞复苏、细胞传代、N阶段细胞培养、蛋白纯化、辅料添加以及单克隆抗体中间体及其他生物样品的其他制备工艺等流程。东曜药业须向药明生物交付合共十(10)批符合相关抗体试生产规格的单克隆抗体中间体。就每批单克隆抗体中间体而言，将根据所需产量采用合适的中试生物反应器(50升、200升或500升)，而完整服务交付范围涵盖工艺开发或技术转移、上游细胞扩增、下游纯化及原液灌装等。

根据上述服务规格，每批单克隆抗体中间体的价格为人民币190万元。东曜药业将按总费用人民币1900万元向药明生物提供工艺开发及制造服务。

公告称，订立工艺开发及制造服务协议有助于东曜药业实现深化其技术诀窍、提升其工艺水平并巩固其交付单克隆抗体及其他生物样品工艺开发服务往绩的目标。此举将提升东曜药业在现有及潜在客户中的声誉，并可能支持未来业务发展及合作机会。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2644795877"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644795877\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644795877?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-17 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644795877","market":"us","top_or_hot":-1,"title":"东曜药业-B(01875)与药明合联(02268)订立工艺开发及制造服务协议","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01875\">东曜药业-B</a>(01875)及<a href=\"https://laohu8.com/S/02268\">药明合联</a>(02268)联合公布，2026年6月16日，东曜药业与<a href=\"https://laohu8.com/S/02269\">药明生物</a>订立工艺开发及制造服务协议，据此，东曜药业将向药明<a href=\"https://laohu8.com/S/000504\">生物</a>提供工艺开发及制造服务。</p><p>根据工艺开发及制造服务协议，东曜药业同意向药明生物提供有关单克隆抗体中间体生产的工艺开发及制造服务。该等服务涵盖细胞复苏、细胞传代、N阶段细胞培养、蛋白纯化、辅料添加以及单克隆抗体中间体及其他生物样品的其他制备工艺等流程。东曜药业须向药明生物交付合共十(10)批符合相关抗体试生产规格的单克隆抗体中间体。就每批单克隆抗体中间体而言，将根据所需产量采用合适的中试生物反应器(50升、200升或500升)，而完整服务交付范围涵盖工艺开发或技术转移、上游细胞扩增、下游纯化及原液灌装等。</p><p>根据上述服务规格，每批单克隆抗体中间体的价格为人民币190万元。东曜药业将按总费用人民币1900万元向药明生物提供工艺开发及制造服务。</p><p>公告称，订立工艺开发及制造服务协议有助于东曜药业实现深化其技术诀窍、提升其工艺水平并巩固其交付单克隆抗体及其他生物样品工艺开发服务往绩的目标。此举将提升东曜药业在现有及潜在客户中的声誉，并可能支持未来业务发展及合作机会。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东曜药业-B(01875)与药明合联(02268)订立工艺开发及制造服务协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东曜药业-B(01875)与药明合联(02268)订立工艺开发及制造服务协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-17 06:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1455265.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，东曜药业-B(01875)及药明合联(02268)联合公布，2026年6月16日，东曜药业与药明生物订立工艺开发及制造服务协议，据此，东曜药业将向药明生物提供工艺开发及制造服务。根据工艺开发及制造服务协议，东曜药业同意向药明生物提供有关单克隆抗体中间体生产的工艺开发及制造服务。该等服务涵盖细胞复苏、细胞传代、N阶段细胞培养、蛋白纯化、辅料添加以及单克隆抗体中间体及其他生物样品的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1455265.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1455265.html","article_id":"2644795877","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644795877","pubTimestamp":1781649048,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，东曜药业-B 及药明合联联合公布，2026年6月16日，东曜药业与药明生物订立工艺开发及制造服务协议，据此，东曜药业将向药明生物提供工艺开发及制造服务。东曜药业须向药明生物交付合共十批符合相关抗体试生产规格的单克隆抗体中间体。公告称，订立工艺开发及制造服务协议有助于东曜药业实现深化其技术诀窍、提升其工艺水平并巩固其交付单克隆抗体及其他生物样品工艺开发服务往绩的目标。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1141":"生命科学工具和服务","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01875":"东曜药业-B","02268":"药明合联","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT BY TOT BIOPHARM-B (01875) AND WUXI UNITED (02268)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1.5,"01875":1.5},"content_text":"智通财经APP讯，东曜药业-B(01875)及药明合联(02268)联合公布，2026年6月16日，东曜药业与药明生物订立工艺开发及制造服务协议，据此，东曜药业将向药明生物提供工艺开发及制造服务。根据工艺开发及制造服务协议，东曜药业同意向药明生物提供有关单克隆抗体中间体生产的工艺开发及制造服务。该等服务涵盖细胞复苏、细胞传代、N阶段细胞培养、蛋白纯化、辅料添加以及单克隆抗体中间体及其他生物样品的其他制备工艺等流程。东曜药业须向药明生物交付合共十(10)批符合相关抗体试生产规格的单克隆抗体中间体。就每批单克隆抗体中间体而言，将根据所需产量采用合适的中试生物反应器(50升、200升或500升)，而完整服务交付范围涵盖工艺开发或技术转移、上游细胞扩增、下游纯化及原液灌装等。根据上述服务规格，每批单克隆抗体中间体的价格为人民币190万元。东曜药业将按总费用人民币1900万元向药明生物提供工艺开发及制造服务。公告称，订立工艺开发及制造服务协议有助于东曜药业实现深化其技术诀窍、提升其工艺水平并巩固其交付单克隆抗体及其他生物样品工艺开发服务往绩的目标。此举将提升东曜药业在现有及潜在客户中的声誉，并可能支持未来业务发展及合作机会。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}